{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:43:17Z","timestamp":1790008997660,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T00:00:00Z","timestamp":1308614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00228-011-1078-4","type":"journal-article","created":{"date-parts":[[2011,6,20]],"date-time":"2011-06-20T09:36:06Z","timestamp":1308562566000},"page":"1223-1229","source":"Crossref","is-referenced-by-count":30,"title":["Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting"],"prefix":"10.1007","volume":"67","author":[{"given":"Osman","family":"G\u00f6kalp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Gunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"\u00c7am","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Cure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Numan","family":"Tamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,21]]},"reference":[{"issue":"6","key":"1078_CR1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00257338","volume":"24","author":"K Asplund","year":"1983","unstructured":"Asplund K, Wiholm BE, Lithner F (1983) Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24(6):412\u2013417","journal-title":"Diabetologia"},{"issue":"7","key":"1078_CR2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-2003-44287","volume":"111","author":"A Holstein","year":"2003","unstructured":"Holstein A, Egberts EH (2003) Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 111(7):405\u2013414","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"12","key":"1078_CR3","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2165\/00003088-200544120-00002","volume":"44","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Roots I, Goldammer M, Rosenkranz B et al (2005) Effect of genetic polymorphisms in cytochrome P450 (CYP) 2\u00a0C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44(12):1209\u20131225","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1078_CR4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2125.2007.02943.x","volume":"64","author":"DJ Elliot","year":"2007","unstructured":"Elliot DJ, Suharjono LBC, Gillam EM et al (2007) Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol 64(4):450\u2013457","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1078_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00228-009-0736-2","volume":"66","author":"B Tan","year":"2009","unstructured":"Tan B, Zhang YF, Chen XY, Zhao XH et al (2009) The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur J Clin Pharmacol 66(2):145\u2013151","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1078_CR6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","volume":"12","author":"CR Lee","year":"2002","unstructured":"Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2\u00a0C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12(3):251\u2013263","journal-title":"Pharmacogenetics"},{"issue":"3","key":"1078_CR7","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1006\/bbrc.1998.9992","volume":"254","author":"U Yasar","year":"1999","unstructured":"Yasar U, Eliasson E, Dahl ML, Johansson I et al (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254(3):628\u2013631","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"1078_CR8","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2217\/pgs.09.96","volume":"10","author":"G Ragia","year":"2009","unstructured":"Ragia G, Petridis I, Tavridou A, Christakidis D et al (2009) Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10(11):1781\u20131787","journal-title":"Pharmacogenomics"},{"issue":"1","key":"1078_CR9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2125.2005.02379.x","volume":"60","author":"A Holstein","year":"2005","unstructured":"Holstein A, Plaschke A, Ptak M, Egberts EH et al (2005) Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 60(1):103\u2013106","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1078_CR10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14740338.2010.492777","volume":"9","author":"A Holstein","year":"2011","unstructured":"Holstein A, Hammer C, Hahn M, Kulamadayil NS et al (2011) Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 9(5):675\u2013681","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1078_CR11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.clpt.6100273","volume":"83","author":"ML Becker","year":"2008","unstructured":"Becker ML, Visser LE, Trienekens PH, Hofman A et al (2008) Cytochrome P450 2\u00a0C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 83(2):288\u2013292","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1078_CR12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z Desta","year":"2002","unstructured":"Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2\u00a0C19 genetic polymorphism. Clin Pharmacokinet 41(12):913\u2013958","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1078_CR13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103\u2013113","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1078_CR14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2217\/14622416.10.1.43","volume":"10","author":"G Ragia","year":"2009","unstructured":"Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG (2009) Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 10(1):43\u201349","journal-title":"Pharmacogenomics"},{"issue":"3","key":"1078_CR15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2710.2009.01134.x","volume":"35","author":"H Shao","year":"2010","unstructured":"Shao H, Ren XM, Liu NF, Chen GM et al (2010) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther 35(3):351\u2013360","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1078_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2125.2007.02846.x","volume":"64","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Si D, Chen X, Lin N et al (2007) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol 64(1):67\u201374","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1078_CR17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B et al (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7):597\u2013607","journal-title":"Pharmacogenetics"},{"issue":"1","key":"1078_CR18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1479-7364-3-1-7","volume":"3","author":"CL Aquilante","year":"2008","unstructured":"Aquilante CL, Bushman LR, Knutsen SD, Burt LE et al (2008) Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics 3(1):7\u201316","journal-title":"Hum Genomics"},{"issue":"4","key":"1078_CR19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0009-9236(03)00228-5","volume":"74","author":"M Niemi","year":"2003","unstructured":"Niemi M, Leathart JB, Neuvonen M, Backman JT et al (2003) Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74(4):380\u2013387","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1078_CR20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/dmd.107.018010","volume":"36","author":"A Tornio","year":"2008","unstructured":"Tornio A, Niemi M, Neuvonen PJ, Backman JT (2008) Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 36(1):73\u201380","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"1078_CR21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","volume":"64","author":"N Bahadur","year":"2002","unstructured":"Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D et al (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64(11):1579\u20131589","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1078_CR22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0006-291X(02)02592-5","volume":"299","author":"U Yasar","year":"2002","unstructured":"Yasar U, Lundgren S, Eliasson E, Bennet A et al (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299(1):25\u201328","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"1078_CR23","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.bjp.0707685","volume":"153","author":"H Xu","year":"2008","unstructured":"Xu H, Williams KM, Liauw WS, Murray M et al (2008) Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 153(7):1579\u20131586","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1078_CR24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clpt.2005.03.008","volume":"78","author":"R Wang","year":"2005","unstructured":"Wang R, Chen K, Wen SY, Li J et al (2005) Pharmacokinetics of glimepiride and cytochrome P450 2\u00a0C9 genetic polymorphisms. Clin Pharmacol Ther 78(1):90\u201392","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1078_CR25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1067\/mcp.2002.127495","volume":"72","author":"M Niemi","year":"2002","unstructured":"Niemi M, Cascorbi I, Timm R, Kroemer HK et al (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72(3):326\u2013332","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1078_CR26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00008571-199902000-00010","volume":"9","author":"RS Kidd","year":"1999","unstructured":"Kidd RS, Straughn AB, Meyer MC, Blaisdell J et al (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9(1):71\u201380","journal-title":"Pharmacogenetics"},{"issue":"5","key":"1078_CR27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1124\/dmd.110.036921","volume":"39","author":"D Tomalik-Scharte","year":"2011","unstructured":"Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D et al (2011) Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 39(5):927\u2013932","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-011-1078-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-011-1078-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T12:20:36Z","timestamp":1592655636000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1078-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,21]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1078-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,21]]}}}